Topics

Synthetic Biology Investing in an Age of Open Platforms

02:07 EDT 24 Jul 2019 | Synbiobeta

Today John Cumbers talks to Ursheet Parikh, partner at Mayfield and leader of their biotechnology and health care portfolios. The conversation is about what it takes to scale synthetic biology companies, some of the challenges they face, and how platform technologies in synthetic biology can help float all boats. Ursheet is a proven repeat entrepreneur […]

The post Synthetic Biology Investing in an Age of Open Platforms appeared first on SynBioBeta.

Original Article: Synthetic Biology Investing in an Age of Open Platforms

NEXT ARTICLE

More From BioPortfolio on "Synthetic Biology Investing in an Age of Open Platforms"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...